ANNALS EXPRESS: Carnosine supplementation does not affect serum levels of advanced glycation and precursors of lipoxidation end products in autism: A randomized controlled clinical trial.
Ann Clin Biochem. 2018 Aug 08;:4563218796860
Authors: Ghodsi R, Kheirouri S, Nosrati R
BACKGROUND: Abundant evidence indicates the increased levels of oxidative stress in patients with autism. Advanced glycation end products (AGEs) and advanced lipoxidation end products (ALEs) and their precursors play the major role in increased oxidative stress in numerous metabolic and neurologic diseases. Carnosine is a natural dipeptide with anti-glycation effects. The aim of this trial was to examine the effects of carnosine supplementation on the AGEs and the precursors of ALEs in patients with autism.
METHOD: This randomized double-blind, placebo-controlled clinical trial was conducted on 36 autistic children, 18 in the carnosine group and 18 in the placebo group. The groups received a daily supplement of 500 mg carnosine or placebo for two months, respectively. Plasma levels of glycation and precursors of lipoxidation markers were evaluated by ELISA method.
RESULTS: In all, 63.9% of the autistic children had normal nutritional status. Carnosine supplementation did not significantly alter plasma levels of AGEs and precursors of ALEs in autistic children.
CONCLUSION: The findings indicate that supplementation of carnosine could not change AGEs and precursor of ALEs in autistic children.
PMID: 30089410 [PubMed – as supplied by publisher]